Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-12-043747)

Filing Details

Accession Number:
0001209191-12-043747
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-08-30 15:01:01
Reporting Period:
2012-08-29
Filing Date:
2012-08-30
Accepted Time:
2012-08-30 15:01:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145404 Cornerstone Therapeutics Inc CRTX Pharmaceutical Preparations (2834) 043523569
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1452285 B Joshua Franklin C/O Cornerstone Therapeutics Inc.
1255 Crescent Green Drive, Suite 250
Cary NC 27518		 Vp, Strategy & Bus. Dev. No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-08-29 38,637 $3.90 59,581 No 4 M Direct
Common Stock Disposition 2012-08-29 38,637 $6.86 20,944 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock (Right to Buy) Disposition 2012-08-29 38,637 $0.00 38,637 $3.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2009-07-28 2018-10-31 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.85 to $6.93, inclusive. The reporting person undertakes to provide to Cornerstone Therapeutics Inc., any security holder of Cornerstone Therapeutics Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  2. Vesting of this option was accelerated, in connection with the closing of the transactions contemplated by the Stock Purchase Agreement, by and among Chiesi Farmaceutici SpA, ("Chiesi") and Cornerstone BioPharma Holdings, Ltd., and other related agreements entered into on May 6, 2009.